Developer docs
API playgroundTry for free, no card

Search company profiles

OrderlyMeds

Full company profile

uuid00064te

Namestring
OrderlyMeds
Legal namestring
OrderlyMeds LLC
Websiteurl
orderlymeds.com
Company typeenum
Private
Founded yearint
2023
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAtlanta, United States
HQ citystring
Atlanta
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
weight loss medications, telemedicine platform, GLP-1 treatments, compounded semaglutide, online weight management
Industry3 codes
PRIMARYHLALAAAD
Prescription-Based Digital Clinics (Condition-Specific Rx Programs)
Healthcare & Life Sciences/Telehealth Platforms/Direct-to-Consumer Virtual Care Platforms
SECONDARYHLALAIAH
Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHSABAIAE
Medication Reconciliation & Treatment Adherence Coordination
Home & Personal Services/Elder Care & In-Home Care Services/Care Coordination & Geriatric Care Management
NAICS code2 codes
  • Offices of Physicians6211
  • Other Ambulatory Health Care Services6219
SIC code2 codes
  • Services-Health Services8000
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Direct-to-consumer telemedicine weight management
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1GLP-1 Medication Sales
TypeSubscription Recurring
Description

Monthly subscription-style payments for GLP-1 and GLP-1/GIP medications, including both compounded formulations and brand-name drugs (Wegovy, Zepbound). Pricing is tiered with starter programs at discounted rates transitioning to standard monthly rates. No membership fees, no hidden costs. HSA/FSA accepted.

orderlymeds.com
2Affiliate Program
TypeAffiliate Referral
Description

One-time commission payments of $75 for each new customer referred through the affiliate program, plus $25 bonus for each sub-affiliate onboarded.

orderlymeds.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
Pricing details8 tiers
1Compounded GLP-1/GIP (Tirzepatide) Starter Program
ModelSubscriptionBilling cadenceMonthly
Notes

$149/month (2-month starter at $299 total), then $299/month thereafter. For patients new to GLP-1 medications.

orderlymeds.com
2Compounded GLP-1/GIP (Tirzepatide) Transfer Program
ModelSubscriptionBilling cadenceMonthly
Notes

$224/month for patients currently taking a GLP-1 medication ($449 for 2 months).

orderlymeds.com
3Compounded GLP-1 (Semaglutide) Starter Program
ModelSubscriptionBilling cadenceMonthly
Notes

$74/month (2-month starter at $149 total), then $149/month thereafter. For patients new to GLP-1 medications.

orderlymeds.com
4Compounded GLP-1 (Semaglutide) Transfer Program
ModelSubscriptionBilling cadenceMonthly
Notes

$112/month for patients currently taking a GLP-1 medication ($224 for 2 months).

orderlymeds.com
5Zepbound (Brand-name GLP-1/GIP)
ModelSubscriptionBilling cadenceMonthly
Notes

$1,498/month for brand-name Zepbound (tirzepatide) pen.

orderlymeds.com
6Wegovy (Brand-name GLP-1)
ModelSubscriptionBilling cadenceMonthly
Notes

$1,839/month for brand-name Wegovy (semaglutide) pen.

orderlymeds.com
7NAD+ Longevity Treatment
ModelSubscriptionBilling cadenceMonthly
Notes

$224/month (1-month), $448 for 2-month supply. Available only for existing GLP-1 customers.

orderlymeds.com
8Sermorelin Longevity Treatment
ModelSubscriptionBilling cadenceMonthly
Notes

$200/month (1-month), $400 for 2-month supply. Available only for existing GLP-1 customers.

orderlymeds.com
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

OrderlyMeds is a direct-to-consumer telemedicine platform that connects individual patients with licensed healthcare providers in all 50 U.S. states to obtain GLP-1 and GLP-1/GIP weight loss medications, including compounded semaglutide and tirzepatide as well as brand-name Wegovy and Zepbound, delivered directly to the patient's door. The all-inclusive monthly subscription bundles provider consultations, medication, syringes, and shipping, and is supplemented by a wellness ecosystem of online therapy, fitness, nutrition, and peer community support. The company recently extended the offering into longevity care with compounded NAD+ and Sermorelin add-on therapies for existing GLP-1 patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Average 15 lbs weight loss on 3-month starter plan
+4 more records
Product overview1 text field

OrderlyMeds is a telemedicine platform providing GLP-1 and GLP-1/GIP weight loss medications with integrated telehealth consultations. The core portfolio centers on Compounded Semaglutide (from $74/mo) and Compounded Tirzepatide (from $149/mo), alongside branded alternatives Wegovy and Zepbound. The platform expanded into longevity wellness with Compounded NAD+ and Compounded Sermorelin treatments. Supporting the medication program is a suite of educational tools including calorie, TDEE, BMI, protein, and weight loss calculators, plus a mobile app, expert webinars, and a private peer community. OrderlyMeds connects patients with licensed healthcare professionals across all 50 states, offering personalized dosing, ongoing provider support, and comprehensive care resources.

Product and service6 records
1Compounded GLP-1 (Semaglutide)
CategoryWeight loss medication (GLP-1)
Description

Compounded semaglutide injection for GLP-1 weight loss treatment, formulated to support individual patient needs with personalized dosing and titration. May include supportive supplements such as B6 or B12 as selected by the prescriber. Prescribed by state-licensed providers via OrderlyMeds' telehealth platform and shipped to patients in all 50 U.S. states from 503A compounding pharmacies. Available via SimpleStart starter program at $74/month for 2 months then $149/month, or a transfer program at $112/month for patients already on GLP-1 therapy.

2Compounded GLP-1/GIP (Tirzepatide)
CategoryWeight loss medication (GLP-1/GIP)
Description

Compounded tirzepatide injection combining GLP-1 and GIP receptor agonism for enhanced weight loss, with personalized dosing and optional supportive supplements such as B6 or B12 as selected by the prescriber. Prescribed via OrderlyMeds' telehealth platform and shipped from U.S. 503A compounding pharmacies. Available via SimpleStart starter at $149/month for 2 months then $299/month, or a transfer program at $224/month for patients already on GLP-1 therapy.

3Wegovy (Semaglutide Brand)
CategoryWeight loss medication (brand-name GLP-1)
Description

FDA-approved brand-name semaglutide 2.4mg injection for chronic weight management, prescribed and dispensed through OrderlyMeds' telehealth platform with ongoing provider support. Available in doses of 0.25mg, 0.5mg, and 1mg, priced at $1,839/month.

4Zepbound (Tirzepatide Brand)
CategoryWeight loss medication (brand-name GLP-1/GIP)
Description

FDA-approved brand-name tirzepatide injection mimicking both GLP-1 and GIP hormones for weight loss, prescribed and dispensed through OrderlyMeds' telehealth platform with ongoing provider support. Available in doses from 2.5mg to 15mg, priced at $1,498/month.

5Compounded NAD+ Longevity Treatment
CategoryLongevity and wellness therapy
Description

Compounded NAD+ (nicotinamide adenine dinucleotide) wellness therapy, a naturally occurring coenzyme involved in cellular energy production and repair, prescribed as part of a clinically supervised wellness program by OrderlyMeds' licensed providers. Available only to existing GLP-1 customers, in 1-month ($224) or 2-month ($448) plans.

6Compounded Sermorelin Longevity Treatment
CategoryLongevity and peptide therapy
Description

Compounded Sermorelin peptide therapy, a synthetic analog of growth hormone-releasing hormone (GHRH) that interacts with the pituitary gland to support natural growth hormone production, recovery, and lean muscle maintenance. Prescribed by OrderlyMeds' licensed providers and available only to existing GLP-1 customers, at $200/month or $400 for 2 months.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeGTM or Marketing Partner
Description

BetterHelp provides online therapy services to OrderlyMeds customers. New customers receive one free month of BetterHelp therapy as part of the $3,700 value of included perks. This partnership addresses the mental health component of weight loss journeys.

2Trainerize
Strategic tierCoreTypeGTM or Marketing Partner
Description

Trainerize powers the fitness app offered to OrderlyMeds customers, providing workout plans, exercise tracking, and direct trainer support to help maintain healthy lifestyles during GLP-1 treatment.

orderlymeds.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Trifecta offers GLP-1 friendly meal delivery with 50% off first order and 15% off subsequent orders for OrderlyMeds customers, supporting nutrition goals during weight loss treatment.

Strategic tierMinorTypeGTM or Marketing Partner
Description

GLP-1 Enhanced provides educational nutrition guides ($100 off GLP-1 Nutrition Blueprint and Mastering Your Taper guides) to help customers optimize nutrition and learn how to transition off GLP-1 medications.

Strategic tierCoreTypeTechnology or Integration
Description

503A designated compounding pharmacy partner that prepares customized GLP-1 and GLP-1/GIP medications for OrderlyMeds patients. Adheres to USP standards and FDA regulations.

6SmartPharmaRx
Strategic tierCoreTypeTechnology or Integration
Description

503A designated compounding pharmacy partner operating in the U.S., preparing customized GLP-1 medications for OrderlyMeds patients with rigorous testing for sterility and potency.

orderlymeds.com
Strategic tierCoreTypeTechnology or Integration
Description

503A designated compounding pharmacy partner preparing customized GLP-1 medications for OrderlyMeds patients in the U.S.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Ro
TypeDirect peer
Description

Ro is a direct-to-consumer telehealth company offering weight loss via branded and compounded GLP-1s through its Body Program, with provider consultations, home delivery, and ongoing coaching. Ro is directly comparable to OrderlyMeds in business model (DTC, subscription, telehealth-prescribed GLP-1s) and overlaps heavily on customer segment.

TypeDirect peer
Description

PlushCare is a telehealth provider (acquired by Accolade) offering online weight loss visits, GLP-1 prescriptions, and ongoing care from licensed physicians. It is a direct peer in online physician-prescribed obesity care, though it leans more on insurance billing than OrderlyMeds' cash-pay model.

TypeDirect peer
Description

Hims & Hers is a public direct-to-consumer telehealth platform offering prescription and OTC treatments, with a fast-growing GLP-1 weight loss program. It is the closest scaled competitor to OrderlyMeds, using a similar subscription telehealth model with online consultations, shipped medication, and bundled support services, and operates at materially larger scale with insurance partnerships.

TypeDirect peer
Description

Calibrate is a clinician-guided, online metabolic health program combining GLP-1 medication with coaching on food, sleep, exercise, and emotional health. Its bundled medication-plus-coaching structure mirrors OrderlyMeds' support ecosystem model, even though Calibrate is more insurance-aligned.

TypeDirect peer
Description

Found is a DTC weight care company prescribing branded and compounded GLP-1 medications alongside provider coaching and behavioral support. It is a direct peer to OrderlyMeds in telehealth-based obesity care with a similar subscription plus coaching model.

TypeBroad incumbent
Description

WeightWatchers Clinic provides clinician-prescribed GLP-1 medications bundled with the WeightWatchers behavioral program. As an established consumer health brand, it competes with OrderlyMeds in the medication-plus-lifestyle support category and brings significant brand and member-base advantages.

TypeDirect peer
Description

Henry Meds is a telehealth platform specializing in compounded GLP-1 weight loss medications with cash-pay pricing, similar to OrderlyMeds. It is a direct peer in compounded semaglutide/tirzepatide prescribing via telehealth, competing for the same price-sensitive cash-pay patient base.

TypeDirect peer
Description

LifeMD is a telehealth company selling weight management programs that include GLP-1 prescriptions, provider consultations, and home delivery. It directly competes with OrderlyMeds in DTC medical weight loss and overlaps on compounded semaglutide/tirzepatide offerings.

TypeBroad incumbent
Description

Eli Lilly's DTC platform sells Zepbound directly to consumers and bypasses compounding pharmacies. As the manufacturer of tirzepatide, Lilly is a broad incumbent that competes head-on with OrderlyMeds' core weight loss offering and has the supply and pricing power to disrupt compounders.

TypeBroad incumbent
Description

Novo Nordisk's NovoCare program offers Wegovy directly to cash-paying patients at a discounted cash price. As the manufacturer of semaglutide and Wegovy, Novo Nordisk is a broad incumbent that competes with OrderlyMeds' branded and compounded semaglutide tiers.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OrderlyMeds

Direct-to-consumer telemedicine weight managementorderlymeds.com

OrderlyMeds firmographics

Firmographics
Name
OrderlyMeds
Legal name
OrderlyMeds LLC
Website
https://orderlymeds.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

OrderlyMeds industry classification

Industry
Product category
Direct-to-consumer telemedicine weight management
NAICS
Offices of Physicians (6211), Other Ambulatory Health Care Services (6219)
SIC
Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011)
akta.pro industry
PRIMARYHLALAAAD
Prescription-Based Digital Clinics (Condition-Specific Rx Programs)
Healthcare & Life Sciences/Telehealth Platforms/Direct-to-Consumer Virtual Care Platforms
SECONDARYHLALAIAH
Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHSABAIAE
Medication Reconciliation & Treatment Adherence Coordination
Home & Personal Services/Elder Care & In-Home Care Services/Care Coordination & Geriatric Care Management

Keywords

  • Weight loss medications
  • Telemedicine platform
  • GLP-1 treatments
  • Compounded semaglutide
  • Online weight management

Where OrderlyMeds is headquartered

Location

Headquarters

HQ city
Atlanta
HQ country
United States
HQ region
North America

Offices1 record

Markets served

OrderlyMeds business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

  1. GLP-1 Medication Sales: Monthly subscription-style payments for GLP-1 and GLP-1/GIP medications, including both compounded formulations and brand-name drugs (Wegovy, Zepbound). Pricing is tiered with starter programs at discounted rates transitioning to standard monthly rates. No membership fees, no hidden costs. HSA/FSA accepted.
  2. Affiliate Program: One-time commission payments of $75 for each new customer referred through the affiliate program, plus $25 bonus for each sub-affiliate onboarded.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyCompounded GLP-1/GIP (Tirzepatide) Starter Program
SubscriptionMonthlyCompounded GLP-1/GIP (Tirzepatide) Transfer Program
SubscriptionMonthlyCompounded GLP-1 (Semaglutide) Starter Program
SubscriptionMonthlyCompounded GLP-1 (Semaglutide) Transfer Program
SubscriptionMonthlyZepbound (Brand-name GLP-1/GIP)
SubscriptionMonthlyWegovy (Brand-name GLP-1)
SubscriptionMonthlyNAD+ Longevity Treatment
SubscriptionMonthlySermorelin Longevity Treatment

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

OrderlyMeds product offering

Product offering

Core offering

OrderlyMeds is a direct-to-consumer telemedicine platform that connects individual patients with licensed healthcare providers in all 50 U.S. states to obtain GLP-1 and GLP-1/GIP weight loss medications, including compounded semaglutide and tirzepatide as well as brand-name Wegovy and Zepbound, delivered directly to the patient's door. The all-inclusive monthly subscription bundles provider consultations, medication, syringes, and shipping, and is supplemented by a wellness ecosystem of online therapy, fitness, nutrition, and peer community support. The company recently extended the offering into longevity care with compounded NAD+ and Sermorelin add-on therapies for existing GLP-1 patients.

Product overview

OrderlyMeds is a telemedicine platform providing GLP-1 and GLP-1/GIP weight loss medications with integrated telehealth consultations. The core portfolio centers on Compounded Semaglutide (from $74/mo) and Compounded Tirzepatide (from $149/mo), alongside branded alternatives Wegovy and Zepbound. The platform expanded into longevity wellness with Compounded NAD+ and Compounded Sermorelin treatments. Supporting the medication program is a suite of educational tools including calorie, TDEE, BMI, protein, and weight loss calculators, plus a mobile app, expert webinars, and a private peer community. OrderlyMeds connects patients with licensed healthcare professionals across all 50 states, offering personalized dosing, ongoing provider support, and comprehensive care resources.

Differentiator

Problem solved

Functional benefit

Products and services

  • Compounded GLP-1 (Semaglutide) Compounded semaglutide injection for GLP-1 weight loss treatment, formulated to support individual patient needs with personalized dosing and titration. May include supportive supplements such as B6 or B12 as selected by the prescriber. Prescribed by state-licensed providers via OrderlyMeds' telehealth platform and shipped to patients in all 50 U.S. states from 503A compounding pharmacies. Available via SimpleStart starter program at $74/month for 2 months then $149/month, or a transfer program at $112/month for patients already on GLP-1 therapy.
  • Compounded GLP-1/GIP (Tirzepatide) Compounded tirzepatide injection combining GLP-1 and GIP receptor agonism for enhanced weight loss, with personalized dosing and optional supportive supplements such as B6 or B12 as selected by the prescriber. Prescribed via OrderlyMeds' telehealth platform and shipped from U.S. 503A compounding pharmacies. Available via SimpleStart starter at $149/month for 2 months then $299/month, or a transfer program at $224/month for patients already on GLP-1 therapy.
  • Wegovy (Semaglutide Brand) FDA-approved brand-name semaglutide 2.4mg injection for chronic weight management, prescribed and dispensed through OrderlyMeds' telehealth platform with ongoing provider support. Available in doses of 0.25mg, 0.5mg, and 1mg, priced at $1,839/month.
  • Zepbound (Tirzepatide Brand) FDA-approved brand-name tirzepatide injection mimicking both GLP-1 and GIP hormones for weight loss, prescribed and dispensed through OrderlyMeds' telehealth platform with ongoing provider support. Available in doses from 2.5mg to 15mg, priced at $1,498/month.
  • Compounded NAD+ Longevity Treatment Compounded NAD+ (nicotinamide adenine dinucleotide) wellness therapy, a naturally occurring coenzyme involved in cellular energy production and repair, prescribed as part of a clinically supervised wellness program by OrderlyMeds' licensed providers. Available only to existing GLP-1 customers, in 1-month ($224) or 2-month ($448) plans.
  • Compounded Sermorelin Longevity Treatment Compounded Sermorelin peptide therapy, a synthetic analog of growth hormone-releasing hormone (GHRH) that interacts with the pituitary gland to support natural growth hormone production, recovery, and lean muscle maintenance. Prescribed by OrderlyMeds' licensed providers and available only to existing GLP-1 customers, at $200/month or $400 for 2 months.

Quantifiable outcome

  • Average 15 lbs weight loss on 3-month starter plan
  • +4 more outcomes

Companies that use OrderlyMeds

Customer profile

Named customers6 records

Segments2 records

Ideal customer profiles2 records

OrderlyMeds technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature3 records

OrderlyMeds partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • BetterHelpcoreGTM or Marketing PartnerBetterHelp provides online therapy services to OrderlyMeds customers. New customers receive one free month of BetterHelp therapy as part of the $3,700 value of included perks. This partnership addresses the mental health component of weight loss journeys.
  • TrainerizecoreGTM or Marketing PartnerTrainerize powers the fitness app offered to OrderlyMeds customers, providing workout plans, exercise tracking, and direct trainer support to help maintain healthy lifestyles during GLP-1 treatment.
  • Trifecta NutritionminorGTM or Marketing PartnerTrifecta offers GLP-1 friendly meal delivery with 50% off first order and 15% off subsequent orders for OrderlyMeds customers, supporting nutrition goals during weight loss treatment.
  • GLP-1 EnhancedminorGTM or Marketing PartnerGLP-1 Enhanced provides educational nutrition guides ($100 off GLP-1 Nutrition Blueprint and Mastering Your Taper guides) to help customers optimize nutrition and learn how to transition off GLP-1 medications.
  • PerfectRx/PerfectionRxcoreTechnology or Integration503A designated compounding pharmacy partner that prepares customized GLP-1 and GLP-1/GIP medications for OrderlyMeds patients. Adheres to USP standards and FDA regulations.
  • SmartPharmaRxcoreTechnology or Integration503A designated compounding pharmacy partner operating in the U.S., preparing customized GLP-1 medications for OrderlyMeds patients with rigorous testing for sterility and potency.
  • CasacoreTechnology or Integration503A designated compounding pharmacy partner preparing customized GLP-1 medications for OrderlyMeds patients in the U.S.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

OrderlyMeds competitors and assessment

Company assessment

Direct peers

  • Ro: Ro is a direct-to-consumer telehealth company offering weight loss via branded and compounded GLP-1s through its Body Program, with provider consultations, home delivery, and ongoing coaching. Ro is directly comparable to OrderlyMeds in business model (DTC, subscription, telehealth-prescribed GLP-1s) and overlaps heavily on customer segment.
  • PlushCare: PlushCare is a telehealth provider (acquired by Accolade) offering online weight loss visits, GLP-1 prescriptions, and ongoing care from licensed physicians. It is a direct peer in online physician-prescribed obesity care, though it leans more on insurance billing than OrderlyMeds' cash-pay model.
  • Hims & Hers Health: Hims & Hers is a public direct-to-consumer telehealth platform offering prescription and OTC treatments, with a fast-growing GLP-1 weight loss program. It is the closest scaled competitor to OrderlyMeds, using a similar subscription telehealth model with online consultations, shipped medication, and bundled support services, and operates at materially larger scale with insurance partnerships.
  • Calibrate: Calibrate is a clinician-guided, online metabolic health program combining GLP-1 medication with coaching on food, sleep, exercise, and emotional health. Its bundled medication-plus-coaching structure mirrors OrderlyMeds' support ecosystem model, even though Calibrate is more insurance-aligned.
  • Found: Found is a DTC weight care company prescribing branded and compounded GLP-1 medications alongside provider coaching and behavioral support. It is a direct peer to OrderlyMeds in telehealth-based obesity care with a similar subscription plus coaching model.
  • Henry Meds: Henry Meds is a telehealth platform specializing in compounded GLP-1 weight loss medications with cash-pay pricing, similar to OrderlyMeds. It is a direct peer in compounded semaglutide/tirzepatide prescribing via telehealth, competing for the same price-sensitive cash-pay patient base.
  • LifeMD: LifeMD is a telehealth company selling weight management programs that include GLP-1 prescriptions, provider consultations, and home delivery. It directly competes with OrderlyMeds in DTC medical weight loss and overlaps on compounded semaglutide/tirzepatide offerings.

Broad incumbents

  • WeightWatchers Clinic (formerly Sequence): WeightWatchers Clinic provides clinician-prescribed GLP-1 medications bundled with the WeightWatchers behavioral program. As an established consumer health brand, it competes with OrderlyMeds in the medication-plus-lifestyle support category and brings significant brand and member-base advantages.
  • Eli Lilly (LillyDirect / LillyDirect Pharmacy Solutions): Eli Lilly's DTC platform sells Zepbound directly to consumers and bypasses compounding pharmacies. As the manufacturer of tirzepatide, Lilly is a broad incumbent that competes head-on with OrderlyMeds' core weight loss offering and has the supply and pricing power to disrupt compounders.
  • Novo Nordisk (NovoCare): Novo Nordisk's NovoCare program offers Wegovy directly to cash-paying patients at a discounted cash price. As the manufacturer of semaglutide and Wegovy, Novo Nordisk is a broad incumbent that competes with OrderlyMeds' branded and compounded semaglutide tiers.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

OrderlyMeds social profiles

Digital presence

OrderlyMeds compliance and trust

Trust signal

Compliance2 records

OrderlyMeds financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OrderlyMeds leadership team

Management profile

Number of profiles

Profiles3 records

OrderlyMeds funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OrderlyMeds M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OrderlyMeds

What does OrderlyMeds do?

OrderlyMeds is a direct-to-consumer telemedicine platform that connects individual patients with licensed healthcare providers in all 50 U.S. states to obtain GLP-1 and GLP-1/GIP weight loss medications, including compounded semaglutide and tirzepatide as well as brand-name Wegovy and Zepbound, delivered directly to the patient's door. The all-inclusive monthly subscription bundles provider consultations, medication, syringes, and shipping, and is supplemented by a wellness ecosystem of online therapy, fitness, nutrition, and peer community support. The company recently extended the offering into longevity care with compounded NAD+ and Sermorelin add-on therapies for existing GLP-1 patients.

Is OrderlyMeds a public or private company?

OrderlyMeds is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was OrderlyMeds founded?

OrderlyMeds was founded in 2023. It employs 51 to 100 people.

Where is OrderlyMeds based?

OrderlyMeds is headquartered in Atlanta, United States, in the North America region.

How does OrderlyMeds make money?

Two revenue lines are on record. GLP-1 Medication Sales are the primary driver. The others are affiliate Program.

Who are OrderlyMeds's main competitors?

Direct peers on record are Ro, PlushCare, Hims & Hers Health, Calibrate, Found, Henry Meds and LifeMD. Broad incumbents are WeightWatchers Clinic (formerly Sequence), Eli Lilly (LillyDirect / LillyDirect Pharmacy Solutions) and Novo Nordisk (NovoCare).

Does OrderlyMeds have an API?

No public API is recorded for OrderlyMeds.

What industry is OrderlyMeds in?

OrderlyMeds's product category is Direct-to-consumer telemedicine weight management. Its primary akta.pro industry code is HLALAAAD, Prescription-Based Digital Clinics (Condition-Specific Rx Programs), with a secondary code of HLALAIAH, Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing. Its NAICS code is 6211 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
U.S. Food and Drug AdministrationOrderlyMeds LLC dba OrderlyMeds - 728291 - 06/08/2026The U.S. Food and Drug Administration issued a warning letter to OrderlyMeds LLC on June 8, 2026, citing significant violations identified during a March 2026 review of the company's website, orderlymeds.com, which offers compounded semaglutide and tirzepatide products. The FDA found that OrderlyMeds made false or misleading claims, including displaying its logo on products suggesting it was the compounder when it is not, and falsely representing that its products are sourced from an "FDA-licensed pharmacy," a designation that does not exist under the FD&C Act. The company has been given 15 business days to respond with corrective actions or face legal consequences including seizure and injunction.HypepotamusMeet the CEO Who Turned His Health Journey Into a Platform Helping Over 90,000 People Lose WeightChris Spears, founder and CEO of Atlanta-based telemedicine startup OrderlyMeds, launched the company in January 2024 to provide personalized GLP-1 weight loss treatment and support, growing from 17 initial customers to over 90,000 by late 2025. The bootstrapped company reached $100 million in annual recurring revenue in just 11 months and has expanded from direct-to-consumer services into B2B partnerships with benefit brokers, corporate partners, and pharmacies. OrderlyMeds recently graduated from Georgia's ATDC technology incubator and employs over 160 W2 employees as it diversifies its telemedicine platform into additional healthcare areas.PR NewswireOrderlyMeds' Response to Eli Lilly's Cease-and-Desist LetterOrderlyMeds responded to Eli Lilly's April 1, 2025 cease-and-desist letter regarding Tirzepatide compounding, defending the practice as patient-tailored care. The company stated it will continue providing compounded medications and fight for patient access.MorningstarOrderlyMeds Launches HealthTech Platform for Personalized CareOrderlyMeds announced a new personalized medicine strategy on April 3, 2025, expanding from prescription access to fully customized treatment plans based on comprehensive health analysis. The program will debut with GLP-1 configurations and grow through end of 2025, using bloodwork, DNA, gut biome, and wearable data to tailor blends.Business & FinancialOrderlymeds Launches Healthtech Platform For Personalized CareOrderlyMeds announced a new personalized medicine strategy expanding from prescription access to fully customized treatment plans based on comprehensive health analysis. The program will debut with GLP-1 configurations and grow through 2025, using bloodwork, DNA, gut biome, and wearable data to tailor blends. The company aims to make personalized care accessible and affordable.YahooOrderlyMeds Launches HealthTech Platform for Personalized CareOrderlyMeds announced a new personalized medicine strategy expanding from prescription access to fully customized treatment plans based on comprehensive health analysis. The program will debut with GLP-1 configurations and grow through end of 2025, using bloodwork, DNA, gut biome, and wearable data to tailor blends.PR NewswireOrderlyMeds Launches HealthTech Platform for Personalized CareOrderlyMeds announced a new personalized medicine strategy expanding from prescription access to fully customized treatment plans based on comprehensive health analysis. The program will debut with GLP-1 configurations and grow through 2025, using bloodwork, DNA, gut biome, and wearable data to tailor care.YahooOrderlyMeds Partners with Trifecta to Provide Ultimate Weight Loss SolutionOrderlyMeds and Trifecta announced a partnership to provide GLP-1 friendly meals to OrderlyMeds members. The meals are designed to support the nutritional guidelines for GLP-1 medications, with a focus on low-glycemic, nutrient-dense foods. The collaboration aims to help members develop lasting healthy habits.YahooOrderlyMeds Unveils Innovative Injectable and Oral Semaglutide for Breakthrough Weight-Loss Management in AtlantaOrderlyMeds launched its weight-loss management program in Atlanta, offering injectable and oral semaglutide. The dual-delivery option aims to provide flexible, personalized weight-loss support. The program is now available nationwide.PR NewswireOrderlyMeds Unveils Innovative Injectable and Oral Semaglutide for Breakthrough Weight-Loss Management in AtlantaOrderlyMeds launched its weight-loss management program in Atlanta, offering injectable and oral semaglutide. The dual-delivery option aims to provide flexible, personalized weight-loss support, with the program now available nationwide.